Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
The snapshots in Fig were taken at the
2022-03-26
The snapshots in Fig. 5 were taken at the end of the first platteau i.e. for 5 Å rmsd or 4 ns time. Thus, we can see that the state of the i-motif affects the mechanism of the G-quadruplex unfolding. At acidic pH the stiff structure of the i-motif does not affect the bottom part (the innermost) of t
-
br Materials and methods br Acknowledgments We
2022-03-26
Materials and methods Acknowledgments We are grateful for financial support from the National Natural Science Foundation of China (Grants No. 81661148046 and 81773762, China) and the “Personalized Medicines—Molecular Signature-based Drug Discovery and Development”, Strategic Priority Research
-
br Conclusion In summary a series of novel
2022-03-26
Conclusion In summary, a series of novel GPR40 agonists bearing phenylpropiolic Epidermal Growth Factor (EGF), human recombinant synthesis motif with favorable metabolic stability were prepared and evaluated for their activities as GPR40 agonists. Among them, compound 9 was identified as a struc
-
Through the analysis of various synthetic GPR
2022-03-26
Through the analysis of various synthetic GPR40 agonists as reported in literature, we found that a number of these compounds contained a phenylpropanoic Epidermal Growth Factor (EGF), human recombinant motif which was inspired from naturally occurring medium to long chain fatty acids. For instance,
-
In non Hodgkin lymphoma the catalytic SET domain of the
2022-03-26
In non-Hodgkin lymphoma the catalytic SET domain of the histone methyltransferase EZH2 is subject to recurrent heterozygous missense mutations . These alterations have been observed in ∼20% of patients with diffuse large B cell lymphoma (DLBCL) and ∼10% of patients with follicular lymphoma (FL). The
-
In neurons and neuroendocrine cells the productive fusion
2022-03-26
In neurons and neuroendocrine cells, the productive fusion pathway is thought to initiate with the Munc18-1/Syx1 complex (Ma et al., 2013, Hughson, 2013, Lai et al., 2017). The Munc13-1 MUN domain is able to catalyze opening of Syx1 (the transition from the Munc18-1/Syx1 complex to the SNARE complex
-
br Drugs approved or in
2022-03-26
Drugs approved or in development To date, three drugs: RAL (MK-0518), EVG (GS-9137) and DTG (GSK1349572) [104], have been approved by the FDA. Their structures are shown in Fig. 5. DTG is under development by GlaxoSmithKline (GSK), and studies have shown DTG to be effective in patients with resis
-
In Kdm c germline and forebrain conditional knockout mice
2022-03-26
In Kdm5c germline and forebrain conditional knockout mice, RNA sequencing showed the upregulation of a large set of genes, suggesting that Kdm5c functions primarily as a transcriptional repressor [,]. While no changes in global H3K4me3 levels were observed in the knockout neurons, there were thousan
-
Dihydroartemisinin Treatment with histamine had no effect on
2022-03-26
Treatment with histamine had no effect on histamine H1 receptor expression in HepG2 Dihydroartemisinin (Fig. 1), while knockdown of histamine H1 receptor expression prevented histamine from repressing apo A-I gene expression (Fig. 2). Overexpression of the histamine H1 receptor regulated apo A-I pr
-
br Disclosure statement br Introduction Nitro phenylethane i
2022-03-26
Disclosure statement Introduction 1-Nitro-2-phenylethane is the first nitro compound isolated from plants [1]. It is a volatile compound found in the essential oil of various species, and its presence provides a pleasant odor that resembles the cinnamon scent [2]. The biogenesis of 1-nitro-2-p
-
br Introduction br Mitochondrial dysfunction and cancer br L
2022-03-25
Introduction Mitochondrial dysfunction and cancer Lactate and succinate as oncometabolites Intracellular actions of lactate and succinate as tumor promoters Cell-surface receptors for lactate and succinate and their role in cancer GPR109A as the receptor for butyrate and β-hydroxybu
-
CF patients can suffer from a multitude of hepatobiliary
2022-03-25
CF patients can suffer from a multitude of hepatobiliary problems including gall stones, hepatitis, steatosis and cirrhosis. Hepatobiliary problems are common in pediatric CF patients with reported prevalence rates up to 25% [12,13]. Cystic fibrosis related liver disease (CFLD) was thought to develo
-
br Results and discussion br Conclusion In this
2022-03-25
Results and discussion Conclusion In this study the first binding assays based on a nonlabelled reporter ligand addressing GlyT1 are described. Following the concept of MS Binding Assays recently introduced in our group, binding of the well-known GlyT1 inhibitor Org24598 employed as reporter l
-
br Conclusion br Acknowledgments br Introduction
2022-03-25
Conclusion Acknowledgments Introduction Throughout history, there is literature that supports the notion that animals can be perceived as “healing”. Overall, there is an increased interest in the general field of Animal Assisted Therapy (AAT). Though the field of equine-facilitated psychoth
-
secretin receptor br Materials and methods br Results br Dis
2022-03-25
Materials and methods Results Discussion Quercetin is a relatively abundant bioactive flavonoid with a wide variety of documented physiological effects, which has gained popularity as a nutritional supplement [40]. There is increasing interest in quercetin's anticancer properties (for recen
15621 records 444/1042 page Previous Next First page 上5页 441442443444445 下5页 Last page